Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review

Immune checkpoints assist with self-tolerance and minimize collateral tissue damage when immune responses are activated. Although immune checkpoint inhibitors (CPIs) are characterized by a favorable risk/benefit ratio, immune checkpoint blockade has been associated with a new subset of autoimmune-l...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zoe Apalla, Chryssoula Papageorgiou, Aimilios Lallas, Florentina Delli, Christina Fotiadou, Christina Kemanetzi, Elizabeth Lazaridou
Formato:	article
Lenguaje:	EN
Publicado:	Mattioli1885 2021
Materias:	immune checkpoint inhibitors skin toxicity adverse effects nivolumab pembrolizumab ipilimumab Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/d217a6d3c37346e39c2b74f9ea6109c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d217a6d3c37346e39c2b74f9ea6109c8
record_format	dspace
spelling	oai:doaj.org-article:d217a6d3c37346e39c2b74f9ea6109c82021-11-17T08:28:14ZCutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review10.5826/dpc.1101a1552160-9381https://doaj.org/article/d217a6d3c37346e39c2b74f9ea6109c82021-01-01T00:00:00Zhttp://dpcj.org/index.php/dpc/article/view/1415https://doaj.org/toc/2160-9381 Immune checkpoints assist with self-tolerance and minimize collateral tissue damage when immune responses are activated. Although immune checkpoint inhibitors (CPIs) are characterized by a favorable risk/benefit ratio, immune checkpoint blockade has been associated with a new subset of autoimmune-like toxicities, named immune-related adverse events (irAEs). Dermatologic reactions are among the most prevalent irAE triggered by CPIs. In a majority of cases they are self-limiting and readily manageable. However, it is not uncommon that they result in severe skin involvement and impairment of patients’ quality of life. Awareness of the spectrum of cutaneous irAEs is mandatory for every clinician involved in the management of oncologic patients. The role of the dermatologists is essential because early recognition and appropriate management of skin toxicity may prevent dose modifications and discontinuation of CPIs. The latter is particularly relevant, considering that recent data suggest favorable oncologic response in patients developing irAEs. Zoe ApallaChryssoula PapageorgiouAimilios LallasFlorentina DelliChristina FotiadouChristina KemanetziElizabeth LazaridouMattioli1885articleimmune checkpoint inhibitorsskin toxicityadverse effectsnivolumabpembrolizumabipilimumabDermatologyRL1-803ENDermatology Practical & Conceptual, Vol 11, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immune checkpoint inhibitors skin toxicity adverse effects nivolumab pembrolizumab ipilimumab Dermatology RL1-803
spellingShingle	immune checkpoint inhibitors skin toxicity adverse effects nivolumab pembrolizumab ipilimumab Dermatology RL1-803 Zoe Apalla Chryssoula Papageorgiou Aimilios Lallas Florentina Delli Christina Fotiadou Christina Kemanetzi Elizabeth Lazaridou Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
description	Immune checkpoints assist with self-tolerance and minimize collateral tissue damage when immune responses are activated. Although immune checkpoint inhibitors (CPIs) are characterized by a favorable risk/benefit ratio, immune checkpoint blockade has been associated with a new subset of autoimmune-like toxicities, named immune-related adverse events (irAEs). Dermatologic reactions are among the most prevalent irAE triggered by CPIs. In a majority of cases they are self-limiting and readily manageable. However, it is not uncommon that they result in severe skin involvement and impairment of patients’ quality of life. Awareness of the spectrum of cutaneous irAEs is mandatory for every clinician involved in the management of oncologic patients. The role of the dermatologists is essential because early recognition and appropriate management of skin toxicity may prevent dose modifications and discontinuation of CPIs. The latter is particularly relevant, considering that recent data suggest favorable oncologic response in patients developing irAEs.
format	article
author	Zoe Apalla Chryssoula Papageorgiou Aimilios Lallas Florentina Delli Christina Fotiadou Christina Kemanetzi Elizabeth Lazaridou
author_facet	Zoe Apalla Chryssoula Papageorgiou Aimilios Lallas Florentina Delli Christina Fotiadou Christina Kemanetzi Elizabeth Lazaridou
author_sort	Zoe Apalla
title	Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
title_short	Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
title_full	Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
title_fullStr	Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
title_full_unstemmed	Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
title_sort	cutaneous adverse events of immune checkpoint inhibitors: a literature review
publisher	Mattioli1885
publishDate	2021
url	https://doaj.org/article/d217a6d3c37346e39c2b74f9ea6109c8
work_keys_str_mv	AT zoeapalla cutaneousadverseeventsofimmunecheckpointinhibitorsaliteraturereview AT chryssoulapapageorgiou cutaneousadverseeventsofimmunecheckpointinhibitorsaliteraturereview AT aimilioslallas cutaneousadverseeventsofimmunecheckpointinhibitorsaliteraturereview AT florentinadelli cutaneousadverseeventsofimmunecheckpointinhibitorsaliteraturereview AT christinafotiadou cutaneousadverseeventsofimmunecheckpointinhibitorsaliteraturereview AT christinakemanetzi cutaneousadverseeventsofimmunecheckpointinhibitorsaliteraturereview AT elizabethlazaridou cutaneousadverseeventsofimmunecheckpointinhibitorsaliteraturereview
_version_	1718425830236880896

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review

Ejemplares similares